News Center
Datavant Acquires AetionDatavant Completes Acquisition of AetionDatavant announced the successful completion of its acquisition of Aetion, a leading real-world evidence platform that powers critical decision-making in healthcare. Aetion is now part of Datavant’s Life Sciences business. "This transaction represents the beginning of a promising new chapter together for two industry-leaders whose joint mission is to make real world evidence truly actionable, and we are delighted to welcome the Aetion team to Datavant,” said Kyle Armbrester, CEO of Datavant. With the completion of this acquisition, Datavant is well-positioned to deliver an end-to-end platform for data feasibility and analysis, enabling healthcare and life sciences companies to more efficiently answer research questions about the clinical impact of therapies in development and in market. “We will leverage our complementary capabilities to help create a bridge between different datasets and transform the way data is being leveraged across the drug development continuum,” Armbrester added. Datavant and Aetion have a combined ecosystem of over 300 data partners comprising datasets and insights across electronic health records, claims, specialty pharmacy, registries, imaging, lab, social determinants of health, and more. Source: Datavant media announcement | |
